Infant Bacterial Therapeutics
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-08 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 41.0 KB | |
| 2025-05-08 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | 40.6 KB | |
| 2025-05-07 14:30 |
Quarterly Report
|
Swedish | 550.1 KB | |
| 2025-05-07 14:30 |
Quarterly Report
|
English | 549.5 KB | |
| 2025-02-13 08:30 |
Annual Report
|
Swedish | 577.8 KB | |
| 2025-02-13 08:30 |
Annual Report
|
English | 571.2 KB | |
| 2024-08-28 08:30 |
Interim Report
|
Swedish | 578.3 KB | |
| 2024-08-28 08:30 |
Interim Report
|
English | 594.7 KB | |
| 2024-08-15 16:44 |
Regulatory News Service
Infant Bacterial Therapeutics patent godkänt i USA
|
Swedish | 48.9 KB | |
| 2024-08-15 16:44 |
Regulatory News Service
Patent for Infant Bacterial Therapeutics has been approved in the USA
|
English | 48.4 KB | |
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” is completed
|
English | 52.7 KB | |
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” är avslutad
|
Swedish | 53.8 KB | |
| 2024-05-08 18:11 |
Declaration of Voting Results & Voting Rights Announcements
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 44.2 KB | |
| 2024-05-08 18:11 |
Declaration of Voting Results & Voting Rights Announcements
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | 44.0 KB | |
| 2024-05-07 16:00 |
Interim Report
|
Swedish | 573.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-14 | Maria Ekdahl | Other | Buy | 500 | 17,000.00 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 839 | 79,033.80 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 161 | 15,134.00 SEK |
| 2023-06-09 | Maria Ekdahl | Other | Buy | 1,086 | 49,956.00 SEK |
| 2023-05-23 | Anders Kronström | Other | Buy | 1,329 | 56,482.50 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 851 | 36,593.00 SEK |
| 2023-05-23 | Maria Ekdahl | Other | Buy | 465 | 19,995.00 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,377.20 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,269.92 SEK |
| 2023-05-22 | Maria Ekdahl | Other | Buy | 709 | 30,487.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Xspray Pharma | Sweden | XSPRAY | |
|
Y.B Urban Renewal - Residential Development LTD | Israel | CSURE-M | |
|
Zentiva 2 | Slovakia | SKF | |
|
Zentiva S.A. | Romania | SCD |